BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lingas G, Rosenke K, Safronetz D, Guedj J. Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin. PLoS Comput Biol 2021;17:e1008535. [PMID: 33411731 DOI: 10.1371/journal.pcbi.1008535] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Nande A, Hill AL. The risk of drug resistance during long-acting antimicrobial therapy. Proc R Soc B 2022;289. [DOI: 10.1098/rspb.2022.1444] [Reference Citation Analysis]
2 Garry RF. Lassa fever - the road ahead. Nat Rev Microbiol 2022. [PMID: 36097163 DOI: 10.1038/s41579-022-00789-8] [Reference Citation Analysis]
3 Marlin R, Desjardins D, Contreras V, Lingas G, Solas C, Roques P, Naninck T, Pascal Q, Behillil S, Maisonnasse P, Lemaitre J, Kahlaoui N, Delache B, Pizzorno A, Nougairede A, Ludot C, Terrier O, Dereuddre-Bosquet N, Relouzat F, Chapon C, Ho Tsong Fang R, van der Werf S, Rosa Calatrava M, Malvy D, de Lamballerie X, Guedj J, Le Grand R. Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates. Nat Commun 2022;13:5108. [PMID: 36042198 DOI: 10.1038/s41467-022-32565-w] [Reference Citation Analysis]
4 Zadeh VR, Afowowe TO, Abe H, Urata S, Yasuda J. Potential and action mechanism of favipiravir as an antiviral against Junin virus. PLoS Pathog 2022;18:e1010689. [DOI: 10.1371/journal.ppat.1010689] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Antunes JC, Moreira IP, Gomes F, Cunha F, Henriques M, Fangueiro R. Recent Trends in Protective Textiles against Biological Threats: A Focus on Biological Warfare Agents. Polymers (Basel) 2022;14:1599. [PMID: 35458353 DOI: 10.3390/polym14081599] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Joseph AA, Fasipe OJ, Joseph OA, Olatunji OA. Contemporary and emerging pharmacotherapeutic agents for the treatment of Lassa viral haemorrhagic fever disease. J Antimicrob Chemother 2022:dkac064. [PMID: 35296886 DOI: 10.1093/jac/dkac064] [Reference Citation Analysis]
7 Salam AP, Duvignaud A, Jaspard M, Malvy D, Carroll M, Tarning J, Olliaro PL, Horby PW. Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing. PLoS Negl Trop Dis 2022;16:e0010289. [PMID: 35353804 DOI: 10.1371/journal.pntd.0010289] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
8 Thielebein A, Ighodalo Y, Taju A, Olokor T, Omiunu R, Esumeh R, Ebhodaghe P, Ekanem A, Igenegbale G, Giwa R, Renevey A, Hinzmann J, Müller J, Pallasch E, Pahlmann M, Guedj J, Nwatuzor J, Femi Babatunde O, Adomeh DI, Asogun D, Akpede N, Okogbenin S, Günther S, Oestereich L, Duraffour S, Ogbaini-emovon E. Virus persistence after recovery from acute Lassa fever in Nigeria: a 2-year interim analysis of a prospective longitudinal cohort study. The Lancet Microbe 2022;3:e32-40. [DOI: 10.1016/s2666-5247(21)00178-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
9 Zadeh VR, Urata S, Afowowe TO, Yasuda J. Potential and action mechanism of favipiravir as an antiviral against Junin virus.. [DOI: 10.1101/2021.12.14.472716] [Reference Citation Analysis]
10 Breuil L, Debache A, Giraud-Sauveur F, Glascott-Jones E. [A further step against Lassa fever?]. Med Sci (Paris) 2021;37:1076-9. [PMID: 34851291 DOI: 10.1051/medsci/2021169] [Reference Citation Analysis]
11 Murphy HL, Ly H. Pathogenicity and virulence mechanisms of Lassa virus and its animal modeling, diagnostic, prophylactic, and therapeutic developments. Virulence 2021. [PMID: 34747339 DOI: 10.1080/21505594.2021.2000290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Nande A, Hill AL. The risk of drug resistance during long-acting antimicrobial therapy.. [DOI: 10.1101/2021.07.10.21260044] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Hansen F, Jarvis MA, Feldmann H, Rosenke K. Lassa Virus Treatment Options. Microorganisms 2021;9:772. [PMID: 33917071 DOI: 10.3390/microorganisms9040772] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]